Navigation Links
Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
Date:2/23/2009

luding, but not limited to, the statements regarding the timing of ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, the timing of CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure, the effect of initial doses of ATPace, the benefits of ATPace, the estimated market of the applications of ATPace, the filing of A new Drug Application and our chances of an efficient testing and drug approval process. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, the market may not be as anticipated and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.

'/>"/>
SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
2. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
4. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
5. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
6. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
7. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
8. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
9. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
10. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
11. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/23/2015)... 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, modernized ... ingredients (API) today announced the business and development progress ... 1. Following the September 2014 JCM application (No. ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... 14, 2012 The Merz Pharma Group today announced ... of the US holding company, Merz Inc., effective March ... overall responsibility for the Medical Dermatology global business unit ... North American companies: Merz Pharmaceuticals, LLC, Merz Aesthetics, Inc. ...
... Smith, among the nation,s largest pharmaceutical wholesalers, today ... chief financial officer (CFO). Mr. Williams, who served recently ... chairman and chief executive Dale Smith, and joins ... (Photo:  http://photos.prnewswire.com/prnh/20120314/NY69737 ) ...
Cached Medicine Technology:The Merz Pharma Group Appoints William D. Humphries As New North American Chief Executive Officer 2H. D. Smith Appoints Bill Williams Chief Financial Officer 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Recently, Weddingshe.com has ... catalog, and has announced its highest annual revenues in the ... on its popular glamorous wedding dresses. , According to the ... important wedding dress promotions for them in 2015. This point ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
(Date:1/22/2015)... State Forestry Institute of Mecklenburg-Vorpommern in Germany ... from GEOSYSTEMS, a dedicated Hexagon Geospatial and Intergraph partner ... Geospatial’s ERDAS APOLLO for cataloging, managing, and ... clouds and documents. This effort will enable the State ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... treats mountaineers caught in avalanches and slipped in crevasses. She ... now offered to cope with a new emergency// - the ... for Louisiana on Thursday, one of the worst-affected American coastal ... killed thousands. ,She will set up an emergency ...
... cells grow and spread rapidly. Recent research on the ... is associated //with loss of regulatory protein., , ... estrogen in their laboratory showed a dramatic reduction in ... known as N-CoR . They also found that the ...
... the womb of pregnant women can be damaged by chemicals ... found that these chemicals reach the baby from// the mother ... newborn babies and 42 new mothers. The samples were tested ... positive for 35 samples tested. Some of the umbilical cord ...
... in household dust is sufficient enough to produce ... asthma-related symptoms such as wheezing.// A ... and the prevalence of diagnosed asthma, asthma symptoms, ... strongest for bedroom floor and bedding dust. Households ...
... latest issue of JAMA, which deals with medical education ... US medical schools receive on an average one gift ... per week and often feel that sponsored educational events ... with progressively fewer boundaries between medicine and the pharmaceutical ...
... Japanese Encephalitis epidemic continues to cause deaths in the ... tight-lipped about the toll in a Japanese encephalitis epidemic; ... disease had claimed 591 lives.// ,As many as ... died in Gorakhpur, the town with the best medical ...
Cached Medicine News:Health News:Toxic chemicals found in domestic products poisoning newborn babies 2Health News:Is your house safe enough to protect against asthma attacks? 2Health News:Pharma Companies May Influence The Decisions Of Medical Students 2
Inquire...
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
CTAD tubes contain theophylline, adenosine and dipyridamol. Coagulation and DTAD tubes are for examination of coagulation parameters....
BD Vacutainer Citrate Tubes with 3.2% buffered sodium citrate solution are used for routine coagulation studies....
Medicine Products: